Vicebio Australia Proprietary Limited

This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine aims to protect against three viruses that cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and triggers a strong immune respon…

This early-stage study tests a new vaccine (VXB-241) designed to protect against two viruses that cause serious lung infections in older adults: RSV and HMPV. About 144 healthy adults aged 60-83 (and some younger adults) will receive one dose of the vaccine at different strengths…